Shots:
- Coloplast has acquired implantable tibial nerve stimulation (ITNS) treatment developer Nine Continents Medical for $145M upfront and an additional contingent milestone. ITNS is developed for overactive bladder (OAB)
- Coloplast expected to initiate clinical studies of ITNS in 2021 with the goal to obtain pre-market approval for a Class III device in the US and EU market approvals in the 2024-2025 timeframe
- ITNS is a miniaturized, self-powered unit placed in the lower leg in a short, minimally invasive procedure under local anesthesia. The unit does not require patient activation, recharging, or recurring visits to the doctor and works on the clinically proven MoA of percutaneous tibial nerve stimulation
Click here to read the full press release/ article | Ref: GlobeNewswire | Image: The Job Network
The post Coloplast Acquires Nine Continents Medical first appeared on PharmaShots.
